# Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Canonical URL: https://biopharmsignal.com/news/ZURA/zura-bio-exceeds-enrollment-target-in-both-hidradenitis-suppurativa-hs-systemic--cfd7a19d
Ticker: ZURA
Company: Zura Bio
Source: Zura Bio
Published: 2026-06-29 11:30 EST
Original Source URL: https://investors.zurabio.com/news-releases/news-release-details/zura-bio-exceeds-enrollment-target-both-hidradenitis-suppurativa
## Summary

Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 TibuSURE has exceeded the 80 participant enrollment

## Article Body
Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 TibuSURE has exceeded the 80 participant enrollment
## Recent Company News
- 2026-06-29 11:30 EST — [Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program](https://biopharmsignal.com/news/ZURA/zura-bio-exceeds-enrollment-target-in-both-hidradenitis-suppurativa-hs-systemic--cfd7a19d) — Source: Zura Bio
- 2026-06-25 13:46 EST — [Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer](https://biopharmsignal.com/news/ZURA/zura-bio-expands-leadership-team-with-appointment-of-muzammil-mustufa-as-chief-business-officer) — Source: Zura Bio
- 2026-06-25 13:46 EST — [Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates](https://biopharmsignal.com/news/ZURA/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates) — Source: Zura Bio
- 2026-06-25 13:46 EST — [Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer](https://biopharmsignal.com/news/ZURA/zura-bio-appoints-immunology-industry-leader-sandeep-kulkarni-m-d-as-chief-executive-officer) — Source: Zura Bio
- 2026-06-25 13:46 EST — [Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit](https://biopharmsignal.com/news/ZURA/zura-bio-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit) — Source: Zura Bio
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)